- Home
- LRFC vs ALGS Comparison
LRFC vs ALGS Comparison
Compare LRFC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- ALGS
- Stock Information
- Founded
- LRFC 2013
- ALGS 2018
- Country
- LRFC United States
- ALGS United States
- Employees
- LRFC N/A
- ALGS N/A
- Industry
- LRFC Finance: Consumer Services
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- LRFC Finance
- ALGS Health Care
- Exchange
- LRFC Nasdaq
- ALGS Nasdaq
- Market Cap
- LRFC 50.2M
- ALGS 50.4M
- IPO Year
- LRFC 2013
- ALGS 2020
- Fundamental
- Price
- LRFC $18.86
- ALGS $7.39
- Analyst Decision
- LRFC
- ALGS Strong Buy
- Analyst Count
- LRFC 0
- ALGS 1
- Target Price
- LRFC N/A
- ALGS $70.00
- AVG Volume (30 Days)
- LRFC 11.2K
- ALGS 130.6K
- Earning Date
- LRFC 08-07-2025
- ALGS 08-05-2025
- Dividend Yield
- LRFC 7.58%
- ALGS N/A
- EPS Growth
- LRFC N/A
- ALGS N/A
- EPS
- LRFC N/A
- ALGS N/A
- Revenue
- LRFC $20,544,000.00
- ALGS $3,270,000.00
- Revenue This Year
- LRFC N/A
- ALGS N/A
- Revenue Next Year
- LRFC N/A
- ALGS $51.55
- P/E Ratio
- LRFC N/A
- ALGS N/A
- Revenue Growth
- LRFC 3.11
- ALGS N/A
- 52 Week Low
- LRFC $16.57
- ALGS $3.76
- 52 Week High
- LRFC $26.00
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- LRFC 56.05
- ALGS 53.13
- Support Level
- LRFC $18.53
- ALGS $6.88
- Resistance Level
- LRFC $19.00
- ALGS $8.66
- Average True Range (ATR)
- LRFC 0.39
- ALGS 0.78
- MACD
- LRFC 0.18
- ALGS -0.08
- Stochastic Oscillator
- LRFC 77.87
- ALGS 30.90
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.